Small-molecule inhibition of the SARS-CoV-2 viral protease may represent a promising route for therapy

The drug development system is broken; the COVID-19 pandemic is an opportunity to take a bold step towards accessible and affordable therapies

Expert pathologist Fred Plapp offers a summary of the virus causing COVID-19, its effects, and the pandemic’s evolving status

"Biogen revitalizes hope for Alzheimer’s therapy, but their work highlights why we still need greater selectivity."

How strong partnerships can drive early-phase clinical trials

A new genomic barcode tracker could help spot the rare immune cells that are most effective against cancer

How primary neuronal cell cultures are unraveling the role of amyloid β oligomers in Alzheimer’s disease.

Sitting Down With… Mike Clayman, CEO of Flexion Therapeutics, Inc., Burlington, Massachusetts, USA.

RNA Inhibitors - an exciting avenue for drug development? We collate the findings from the Innovation that Matters series, hosted by WuXi Xpress...

Sitting Down with Michael Tanner, Research Fellow in the School of Engineering and Physical Sciences at Heriot Watt University, Edinburgh, UK.